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Pneumococcal bacteriophage-encoded lysins are modular
proteins that have been shown to act as enzymatic antimicrobial
agents (enzybiotics) in treatment of streptococcal infections.
The first x-ray crystal structures of the Cpl-1 lysin, encoded by
the pneumococcal phage Cp-1, in complex with three bacterial
cell wall peptidoglycan (PG) analogues are reported herein. The
Cpl-1 structure is folded in two well defined modules, one
responsible for anchoring to the pneumococcal cell wall and the
other, a catalytic module, that hydrolyzes the PG. Conforma-
tional rearrangement of Tyr-127 is a critical event in molecular
recognition of a stretch of five saccharide rings of the polymeric
peptidoglycan (cell wall). The PG is bound at a stretch of the
surface that is defined as the peptidoglycan-binding sites 1 and
2, the juncture of which catalysis takes place. The peptidogly-
can-binding site 1 binds to a stretch of three saccharides of the
peptidoglycan in a conformation essentially identical to that of
the peptidoglycan in solution. In contrast, binding of two pepti-
doglycan saccharides at the peptidoglycan-binding site 2 intro-
duces a kink into the solution structure of the peptidoglycan, en
route to catalytic turnover. These findings provide the first
structural evidence on recognition of the peptidoglycan and
shed light on the discrete events of cell wall degradation by
Cpl-1.
Streptococcus pneumoniae is one of the most common and
important human pathogens, which causes serious life-threat-
ening diseases such as acute otitis media, pneumonia, sepsis,
and meningitis. Pneumococcal infections are associated with
high morbidity and mortality, especially among children, the
elderly, and the immune-depressed patients. The widespread
emergence of antibiotic resistance and the lack of highly effec-
tive pneumococcal vaccines against all serotypes of this orga-
nism give urgency to elucidation of the molecular processes
involved in its pathogenicity (1, 2).
The peptidoglycan (PG)3 scaffold of the bacterial cell wall
is a repeating GlcNAc-N-acetylmuramic (MurNAc) disac-
charide (GlcNAc-(-1,4)-MurNAc) unit having a pentapep-
tide attached to the D-lactyl moiety of each MurNAc unit. All
known pneumococcal bacteriophages encode an amidase or a
lysozyme, which hydrolyzes the PG at the final stage of the
phage reproductive cycle, leading to bacterial cell lysis. These
enzymes, known collectively as endolysins, have been shown to
be highly efficient in killing pneumococci in vitro and can erad-
icate this organism from the upper respiratory tract or from the
bloodstream of mice (3, 4) acting as new antimicrobial agents
(i.e. enzybiotics). In addition, Cpl-1 lysin and Pal amidase
encoded by phage Dp-1 act in a synergistic manner in a sepsis
mouse model (5); this synergy has also been confirmed in in
vitro experiments with Cpl-1 and penicillin or gentamicin (6).
Very recently, the creation of a new animal model of otitis
media has been reported (7). Using this new mouse model, it
has been demonstrated that Cpl-1 could eliminate colonization
with S. pneumoniae and prevent the development of otitis
media (7). A paucity of information exists presently on the
mechanisms of lysis of pneumococcal cell wall by the phage-
encoded endolysins at the molecular level.
All known pneumococcal endolysins display a modular
structure. In addition to the catalytic module, all but one pos-
sesses a choline-binding module (CBM) to facilitate their
anchoring to the choline-containing teichoic acid of the pneu-
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mococcal cell wall (8). This CBM is formed by a repeat of about
20 amino acids, found inmultiple tandem copies (ranging from
4 to 18) in a large family of surface proteins (144 members
identified by Pfam) fromGram-positive bacteria and from their
bacteriophages. These proteins, named choline-binding pro-
teins (CBPs) play important physiological functions in pneu-
mococcal virulence (9). Only crystal structures of two complete
CBPs, those of Cpl-1 (10) and Pce (11), have been reported.
Cpl-1 belongs to the GH25 family of glycosyl hydrolases and
cleaves the1–4 glycosidic bond between theMurNAc and the
GlcNAc residues of the pneumococcal PG. Structural knowl-
edge of how this process takes place in Cpl-1 and in all other
members of the GH25 family of glycosyl hydrolases is presently
lacking.
Here we report the crystal structures of the native Cpl-1
lysozyme and of a catalytically inactivemutant variant, referred
to as Cpl-1E94Q, in complex with cell wall PG analogues. The
combination of crystallographic and computational studies has
allowed us to gain unprecedented insights into the recognition
events that lead to the catalytic turnover processes. This knowl-
edge is central in understanding howpneumococcal envelope is
degraded by Cpl-1, but it also sheds light on the important
question of how enzybiotics function against pneumococci and
other Gram-positive bacteria.
EXPERIMENTAL PROCEDURES
PG Analogues Synthesis—The PG analogues 2S5P and
(2S5P)2 were synthesized as described earlier (12, 13).
Expression and Purification of Cpl-1 Endolysin—The native
Cpl-1 lysozyme and its Cpl-1E94Q mutant variant were
expressed in Escherichia coli DH1 (pCIP100) and E. coli DH1
(pCOB7) cells, respectively, and purified from the crude
extracts as described (14).
Crystallization and Data Collection—Native crystals of
Cpl-1 and Cpl-1E94Q were grown using the hanging drop
vapor diffusion method, as reported previously (15). Com-
plexes of the wild-type and mutant
lysozymes with disaccharide di-
peptide GlcNAc-MurNAc-(L-Ala-
D-isoGln) (2S2P), the disaccharide
pentapeptide (GlcNAc-MurNAc-
(L-Ala-D-Glu-L-Lys-D-Ala-D-Ala)
(2S5P), and the tetrasaccharide di-
pentapeptide GlcNAc-MurNAc-
(L-Ala-D-Glu-L-Lys-D-Ala-D-Ala))2
(2S5P)2 (Fig. 1) were obtained by
soaking the crystals of both proteins
in solutions containing the PG ana-
logues. Soaking time was 30 min in
all cases except for the 2S5P where
the time was 18 h; the concentra-
tions for the ligands were 100 mM
for the 2S2P and 25mM for the 2S5P
and the (2S5P)2. GlcNAc and Mur-
NAc monosaccharides, (GlcNAc)2,
(GlcNAc)4, and (GlcNAc)6 oligo-
saccharides, and the PG analogues
MurNAc-(L-Ala-D-isoGln) and
MurNAc-(L-Ala-D-isoGln-L-Lys-D-Ala-D-Ala) were also tested
without success. The x-ray data sets of the wild-type and Cpl-
1E94Q mutant in complex with 2S2P were collected up to 2.3
and 2.0 Å resolution, respectively, using the graphite mono-
chromatic CuK (  1.5418 Å) radiation generated by an
Enraf-Nonius rotating anode generator and a MAR345 image
plate detector. The x-ray data sets of the Cpl-1E94Q in complex
with 2S5P and (2S5P)2 were measured at the ID29 beamline of
the ESRF up to resolutions of 1.8 and 1.7 Å, respectively. Crys-
tals of the four complexes belong to the orthorhombic C2221
space group with one molecule in the asymmetric unit. The
x-ray diffraction data sets were processed and scaled using the
programs MOSFLM (16) and SCALA from the CCP4 package
(17).
Structure Determination and Refinement—All structures
were solved by theMolecular ReplacementMethod. Structures
of lysozyme complexes with 2S2P were solved using the pro-
gram AMoRe (18), whereas those of the Cpl-1E94Q in complex
with 2S5P and (2S5P)2were solved using the programMOLREP
(19). The crystal structure of the native Cpl-1 (10) was used as
the initial model. The models were subjected to successive
refinement cycles with the CNS program (20) and manual
model building used the software package O (21). After this
initial round of refinement, the model was further refined by
iterativemaximum likelihood positional andTLS refinement in
REFMAC5 from the CCP4 package (17). Electron density maps
of excellent quality were obtained for all ligands. In the com-
plexes with 2S2P, the complete ligand molecule was observed.
In the Cpl-1E94Q-2S5P complex, two ligand molecules were
seen in the crystallographic structure. Overall, the resulting
electron density was of excellent quality except for two amino
acid side chains of the linker region betweenmodules (residues
191–200). Description of the atomic composition of the four
complexes together with structure determination parameters
and refinement statistics are summarized in Table 1.
FIGURE 1. Schematic drawing of the three peptidoglycan analogues bound to Cpl-1. 2S2P is disaccharide-
dipeptide, 2S5P is disaccharide-pentapeptide, and (2S5P)2 is tetrasaccharide-di-pentapeptide.
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Docking Studies—The docking studies were carried out
with the FlexiDock module of the SYBYL 6.9 suite of pro-
grams (Tripos Inc., St. Louis). A PG model was constructed
on the basis of the crystallographic complexes, the hexasac-
charide tri-pentapeptide (GlcNAc-MurNAc-(L-Ala-D-Glu-
L-Lys-D-Ala-D-Ala))3 (hereafter (2S5P)3).
The structure of Cpl-1 obtained from x-ray was edited and
prepared. The (2S5P)3model was constructed from the crystal-
lographic complex Cpl-1E94Q-(2S5P)2 by adding the GlcNAc-
MurNAc-(L-Ala-D-Glu-L-Lys-D-Ala-D-Ala) fragment at posi-
tions 1 and 2. In all cases, MMFF94 force field (22, 23)
together with parameters especially derived for carbohydrates
(24) and charges were applied with the use of distance-depend-
ent dielectric constants and conjugate gradient method until
the gradient reached 0.005 kcal mol1Å1. Enzyme-ligand
complexes were built on the basis of
the crystallographic complex and
refined using FlexiDock with a
genetic algorithm (25) to determine
the optimum ligand geometry.
For docking procedure, the pro-
tein was considered rigid except the
residues involved in the binding site
(sphere of 7 Å), whereas the ligands
were considered flexible. Several
runs of flexidock were performed to
obtain a series of model complexes.
These complexeswere analyzed and
clustered in families based on the
following: (i) score energy from
flexidock results; (ii) agreement
between the experimental data and
the theoretical model (the interac-
tions were examined with the LPC program (26)); and (iii) free
energy of binding (Gbind) calculated with Structural Thermo-
dynamics Calculations version 4.3 (27). The representative
conformer from each group was reoptimized.
RESULTS ANDDISCUSSION
Crystal Structures of Cpl-1 in Complex with PG Analogues—
The Cpl-1 structure is folded in two well defined modules con-
nected by a linker (Fig. 2). The catalytic module consists of an
irregular (/)53 barrel where the PG is hydrolyzed. TheCBM
presents six choline-binding repeats (p1–p6) forming a -hair-
pin each and a C-terminal tail of 16 amino acids. The first four
repeats (p1–p4) are folded in a super-helical arrangement (CI
domain, Fig. 2), whereas the other two repeats (p5–p6) and the
C-terminal tail fold as an antiparallel-like six-stranded -sheet
FIGURE 2. Stereo view of the three-dimensional structure of the complex Cpl-1E94Q-(2S5P)2. The catalytic
module of Cpl-1 is in orange; the linker is in yellow; the CBM is in blue (CI domain) and inmagenta (CII domain).
The bound peptidoglycan is drawn in green space-filled representation.
TABLE 1
Structure determination and statistics of the Cpl-1 complexes with the three peptidoglycan analogues
Values in parentheses correspond to the highest resolution shell.
Cpl-1–2S2P Cpl-1E94Q-2S2P Cpl-1E94Q-2S5P Cpl-1E94Q-(2S5P)2
Data collection statistics
Space group C2221 C2221 C2221 C2221
Unit cell parameters
a, Å 80.52 79.96 80.23 79.52
b, Å 96.50 96.44 95.56 97.39
c, Å 127.32 127.07 129.27 127.14
T (K) 120 120 100 100
Wavelength, Å 1.5418 1.5418 0.9760 0.9760
Resolution, Å 25.9 (2.41)–2.26 26.5 (2.08)–1.96 64.6 (1.97)–1.84 63.3 (1.81)–1.69
Total no. of reflections 632,248 388,319 459,898 621,365
No. of unique reflections 22,910 35,314 47,697 57,974
Redundancy 9.3 (9.1) 4.3 (4.2) 5.4 (2.9) 5.5 (3.4)
Completeness, % 99.9 (99.5) 99.4 (100) 96.3 (81.6) 92.6 (71.4)
I/ 20.8 (4.9) 10.9 (3.2) 11.0 (3.0) 10.9 (3.2)
Rrima 0.07 (0.45) 0.08 (0.44) 0.13 (0.61) 0.05 (0.60)
Rpimb 0.02 (0.15) 0.02 (0.14) 0.05 (0.35) 0.12 (0.32)
Wilson plot B-factor 48.5 46.7 18.3 19.6
Refinement statistics
Resolution range, Å 25.9–2.3 26.5–2.0 64.6–1.84 63.3–1.7
Protein non-hydrogen atoms 2763 2763 2763 2763
Ligand non-hydrogen atoms 51 51 90 72
Solvent non-hydrogen atoms 172 275 333 454
Rwork/Rfreec 0.21/0.26 0.21/0.24 0.18/0.22 0.19/0.22
r.m.s.d. bond length, Å 0.007 0.006 0.017 0.006
r.m.s.d. bond angles, ° 1.3 1.3 1.6 1.5
Average B-factor, Å2 43.7 47.6 23.0 20.7
aRrim, redundancy-independent (multiplicity weighted) Rmerge.
b Rpim, precision-indicating (multiplicity weighted) Rmerge.
c R calculated for 7% of data excluded from the refinement.
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(CII domain) that mediates interaction between modules (Fig.
2). The first four repeats provide two canonical choline-binding
sites in Cpl-1, analogous to the same architecture displayed in
other CBPs, such as Pce (11) and C-LytA (28). An additional
choline-binding site, located at the top of theCBM, is formedby
three aromatic residues (Trp-210, Phe-218, and Tyr-238).
Structural studies were performedwith PG analogues shown
in Fig. 1. Superimposition of the structures of the crystallized
complexes with that of the native Cpl-1 gave r.m.s.d. values
ranging from 0.48 to 0.64 Å.
The substrate-binding cleft of
lysozymes and other glycosyl hydro-
lases can usually accommodate sev-
eral saccharide units designated as
positions i (the nonreducing end)
through j. The saccharide units
flanking the scissile glycosidic bond
are assigned as positions 1 and
1. In all Cpl-1 complexes crystal-
lized, the PG analogues were clearly
identified in the electron density
maps located along a groove leading
to the Cpl-1 active site (Fig. 3 and
supplemental Fig. 1). This groove,
hereafter referred to as the pepti-
doglycan-binding site 1 (PGBS1), is
built by a short loop (residues 125–
129) after 5 and by the big loop
(residues 151–173) placed between
6 and 7. The muropeptide ana-
logues 2S2P (Fig. 3A) and 2S5P (Fig.
3B) interact through their GlcNAc
and MurNAc rings with Cpl-1 at
positions 1 and 2, respectively,
whereas the tetrasaccharide ana-
logue (2S5P)2 binds through the
three GlcNAc, MurNAc and Glc-
NAc rings at positions 1, 2, and
3, respectively (Fig. 3C). The
fourth saccharide ring in (2S5P)2 is
not seen in the density. A smaller
electron density was also found near
the active site and was modeled as a
formate ion from the precipitant
solution (supplemental Fig. 1). The
formate ion binding is made possi-
ble by interactions with Ser-13, Lys-
34, andTyr-41. Remarkably, no sub-
strate atomswere found at positions
1 and 2, despite extensive crys-
tallization trials with a wide variety
of smaller sized analogues (data not
shown). The absence of ligand
atoms at positions 1 and 2 can
be explained by the steric restric-
tions imposed by the Cpl-1 crystal
packing at these positions (Trp-210
of a symmetry-related molecule is
ensconced at the putative2 position).
Considering the similarity of structural results among all
three complexes, we discuss here the complex of the protein
with the largest PG analogue (Cpl-1-(2S5P)2). The substrate
analogue binds to the enzyme via two GlcNAc and one Mur-
NAc residues, along with its associated peptide stem. No elec-
tron density was observed for either the terminal MurNAc sac-
charide ring or its stem peptide, but the remainder of the
structure of the (2S5P)2 molecule is well defined in the electron
density map sequestered in the PGBS1 (Fig. 3C and Fig. 4A).
FIGURE 3. Electron density maps observed for ligands of the crystallographic complexes. Stereo view
representations of the complexes Cpl-1-(2S2P) (A), Cpl-1E94Q-(2S5P) (B), and Cpl-1E94Q-(2S5P)2 (C) at the PGBS1.
Electron densitymaps (2Fo Fc) are contoured at 1.0 in gray. Carbon atoms of the ligand are in green, and the
protein is in orange. The two catalytic residues are highlighted in ball and stickswith the carbon atoms in black.
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The GlcNAc ring at position 1 is primarily stabilized by
hydrogen bonds with the hydroxyl group of Tyr-125 and the
carboxylic group of the catalytic Glu-94 (Gln in the inactive
mutant), as well as by hydrophobic
interactions with Ala-151 and Tyr-
153 side chains (Fig. 4B). The Mur-
NAc ring in position 2 makes a
stacking interaction with Tyr-127.
In addition, a polar interaction
exists between the hydroxyl group
of Tyr-127 and that at C-6 of the
MurNAc. The peptide stem is
tightly packed with a Cpl-1 loop
(residues 151–154). No electron
densitywas observed for the last two
amino acids (D-Ala-D-Ala) of the
ligand. We add that the solution
NMR structure of (2S5P)2 had
revealed the L-Lys-D-Ala-D-Ala por-
tion of the stem peptide totally
devoid of structure, consistent with
it being a mobile element (29). This
mobility would appear to be true
also for the D-Ala-D-Ala portion of
the ligand in complex with Cpl-1
and hence its lack of observation in
the electron density map.
AModel of Cpl-1 in Complex with
a Larger Peptidoglycan Segment—
Crystallization trials failed to pro-
vide information on peptidoglycan
binding at positions 1 and 2.
Meroueh et al. (29) recently
reported the NMR solution struc-
ture for (2S5P)2, which revealed that
the saccharide backbone of the
structure produced dihedral angles
for the three consecutive glycosidic
bonds that repeated themselves,
producing a highly regular right-
handed helix for the sugar back-
bone. Interestingly, this same right-
handed helix is also observed in the
three saccharide rings of the Cpl-1-
(2S5P)2, superimposable to the con-
formation determined in solution.
Edified by this knowledge, we
attempted to model a larger struc-
ture for the peptidoglycan into the
active site of our crystal structure
with occupancy at positions 2 to
4. The model revealed contacts of
theMurNAc at position1 and the
GlcNAc at 2, a region (hereafter
referred to as the peptidoglycan-
binding site 2 (PGBS2)) formed by
the active site and the -hairpin
region (residues 34–45), where the
formate ion was found in the crystallographic complexes (Fig.
4A). A network of hydrogen bonds between theN-acetyl group
of sugar at position 1 and residues Tyr-59, Tyr-125, and
FIGURE 4.Details of peptidoglycan recognition by Cpl-1. A, superimposition of the crystallographic coordi-
nates for Cpl-1E94Q-(2S5P)2 (inwhite) with the computational model for Cpl-1-(2S5P)3 (in black). The computa-
tionalmodel traces the crystallographically determinedportions of the structurebut alsoprovides information
on the portions of the structure of the ligand that did not appear in the crystallographic data. Regions involved
in substrate recognition are highlighted in pink for PGBS1, and in blue for PGBS2. The catalytic residues Glu-94
and Asp-10 are in orange. B, stereo view of the crystallographic complex Cpl-1E94Q-(2S5P)2 showing the inter-
actions between Cpl-1 and (2S5P)2. Carbon atoms of the ligand are in green, and the two catalytic residues are
highlighted in orange. Hydrogen bonds are shown as dashed lines. C, stereo view representation of the inter-
actions in Cpl-1-(2S5P)3 with the PG at positions 2 to 3. Ligand and catalytic residues are in green and
orange, respectively, and the formate anion is in cyan.
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Asp-92 was also seen (Fig. 4C). The stem peptide of the Mur-
NAc at position1 experiences a network of hydrophobic and
polar interactions (detailed in supplemental Tables 2 and 3).
These interactions force the1 sugar to acquire a boat confor-
mation that introduces a kink in the PG right-handed helix.
Interactions with GlcNAc at 2 are predicted to take place
mainly through a stacking interaction with His-14.
Implications for the Catalytic Mechanism of Cpl-1—Hydro-
lytic action of lysozymes takes place via a general acid/base
mechanism that requires two acidic amino acids, one behaves
as the proton donor/acid and the other behaves as the nucleo-
phile/base that promotes the hydrolytic attack by a water mol-
ecule. The previously proposed (10) electrophilic and nucleo-
philic residues are Glu-94 and Asp-10, respectively, and are
fully conserved within the GH-25 family. As seen by the short
distances, Asp-182 and Asp-92 make low barrier hydrogen
bonds (30) with the catalytic residues (2.42 Å for Asp-10 to
Asp-182, and 2.59 Å for Asp-92 to Glu-94), with potential
implications for the enzymatic reaction. Furthermore, the dis-
tortion of the conformation of the substrate at position1 to a
higher energy species (boat versus chair conformers) generates
the kink in the substrate, which is likely to be a high energy
species en route to the transition
state for the reaction, as has been
also described for other glycosyl
hydrolases (31).
The distance of 9.5 Å between
the two catalytic residues (Asp-10
andGlu-94) in theCpl-1 structure is
consistent with that expected for an
inverting enzyme (9.0 and 9.5 Å for
inverting - and -glycosidases,
respectively, and 4.8 and 5.3 Å for
retaining - and -glycosidases,
respectively) (32, 33). The distance
of 7.2 Å between Asp-10 and the
anomeric carbon of the1 sugar in
the model of Cpl-1-(2S5P)3 com-
plex could accommodate a water
molecule between them. Asp-10
would activate the water molecule
for attack at the glycosidic bond.
The side chain of Glu-94 is at
H-bond distance of the oxygen of
the 1–4 bond; hence, it is poised
for the transfer of a proton to the
leaving group oxygen, making the
hydrolytic process possible.
Peptidoglycan-binding Mecha-
nism—No significant structural dif-
ferences were found between the
complexes with the native Cpl-1 or
with the catalytically inactive
mutant Cpl-1E94Q upon substrate
binding as deduced by their low
r.m.s.d. values. However, the struc-
ture of the complex with the ligands
reveals a profound conformational
change of the side chain of Tyr-127 (Fig. 5). This movement
involves a change in the values of the two side-chain torsion
angles (1 and 2) of Tyr-127, which experience displacements
of 1 101° and 2 25° from the native to the complexed
state. In the absence of substrate, the side chain of Tyr-127 is
placed in the center of the substrate-binding cleft, making polar
interactions with Tyr-125 and Tyr-153, via their hydroxyl
groups, and a few water molecules (Fig. 5A). In this conforma-
tion, Tyr-127 completely blocks access of the substrate to the
active site at position1. Interaction of the active site with the
PG chain facilitates repositioning of the tyrosine side chain to a
hydrophobic pocket created by Phe-130 and Pro-129 and
places it in a suitable conformation for interacting with the
MurNAc at position2 (Fig. 5B). The displacement of Tyr-127
from the central position in the active site and its subsequent
new interactionwithMurNAc at position2must be pivotal to
catalysis. It is not merely that the repositioning of Tyr-127
makes room for binding of PG, but it also would lower the
energy barrier for the hydrolytic reaction by its interactionwith
the substrate, even though this electrostatic interaction is one
saccharide downstream from the seat of the reaction. Other
observations of note are that substrate analogues lacking the
FIGURE5.Substrate channelbeforeandafter ligandbinding. In the absenceof thePG ligandTyr-127blocks
the entrance to the active site (A); upon ligand binding, Tyr-127 repositions itself to allow access to the sub-
strate (B). Hydrogen bonds are drawn as dashed lines.
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GlcNAc at 1 position or the peptide moiety (of at least two
amino acids) on MurNAc at position 2 fail to bind to Cpl-1.
These specific interactions at positions 1 and 2 might be
crucial in triggering the Tyr-127 movement as a gatekeeper to
the active site and to the onset of catalysis.
The crystallographic complexes showed that Cpl-1 interacts
well with the first two amino acids of MurNAc at position 2
and to a lesser extentwith the third (L-Lys). The expanded com-
putational model reveals that the peptide moiety of the Mur-
NAc at position 1 should be nicely anchored within PGBS2
region (Fig. 4, A and C). This interaction network can explain
why mutation of Glu-37 (a residue within the PGBS2 site) to
alanine or lysine results in a drastic loss of the catalytic activity,
whereas the E37Q mutant variant still retained 67% of activity
(34).
Substrate Recognition in the GH-25 Family—Sequence com-
parison among the GH-25 family and inspection of crystal
structures of Cpl-1, Cellosyl, the muramidase encoded by
Streptomyces coelicolor (35), and the very recently reported
structure of the catalytic domain of PlyB, a lysin from the BcpI
phage (36), allowed us to analyze whether the proposed pepti-
doglycan-Cpl-1 binding model can be applied to other family
members. Besides the catalytic residues, several residues inter-
acting with the MurNAc residue at position 1, such as Tyr-
125 and Tyr-59, are also conserved in the GH-25 family (Fig.
6A). When the PGBS2 region of Cpl-1 is compared with the
FIGURE 6. The structure-based sequence comparison of themembers of the GH25 family. A, sequence alignment of muramidases of the GH25 lysozyme
family: Cpl-1, lysozyme from the pneumococcal phage Cp-1; Cpl-7, lysozyme from the pneumococcal phage Cp-7; LytC, lysozyme from S. pneumoniae; Cellosyl,
lysozyme from S. coelicolorMuller; lysozymes fromChalaropsis and Streptomyces erythraeus andPlyB, lysozyme from thephage BcpI. Residues belonging to the
PGBS1 and PGBS2 regions are in blue and pink, respectively, and the catalytic residues are in orange. B, stereo view representation of the complex Cpl-1-(2S5P)3
(protein residues and ligand in orange and green, respectively) superposed with Cellosyl (violet) and PlyB (cyan) structures. Only residues involved in PG
recognition by Cpl-1 and those conserved in Cellosyl and PlyB are shown.
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equivalent regions in Cellosyl and PlyBcat, one concludes that
the type of amino acids implicated in recognition at position1
by Cpl-1 (Lys-34, Glu-37, Tyr-41, Tyr-59, Phe-61, and Arg-63;
Cpl-1 numbering) is highly conserved (Fig. 6, A and B). His-14,
the side chain of which is proposed to be critical in the stabili-
zation of GlcNAc at the 2 position, is either conserved or
conservatively replaced by an aromatic residue, tyrosine or
tryptophan, as in the case of Cellosyl and PlyBcat (Trp-13 and
Trp-10, respectively). This reinforces the essential role of this
stacking interaction in peptidoglycan recognition at position
2 by the GH-25 family.
Concerning the PGBS1 region, the aromatic residue at posi-
tion 153 (Cpl-1 numbering) stabilizingGlcNAc at1 is system-
atically conserved. However, the critical Tyr-127, whose
motion opens up the active site, is seen only in lysozymes
encoded by pneumococcus and its bacteriophages. However, in
other GH-25 family members, for which structures have been
reported, the Tyr-127 position is also occupied by an aromatic
residue (His-101 in Cellosyl and His-124 in PlyB) (Fig. 6B).
Interestingly, in the case of PlyB, the side chain of His-124 is
placed centrally in the binding site, implying the possibility for
a similar displacement upon substrate binding seen for Tyr-127
in Cpl-1.
Molecular Recognition of Pneumococcal Cell Wall—The
structure of the peptidoglycan bound to Cpl-1 at positions1,
2, and3 is virtually identical to the solution structure of the
fragment, whereas the enzyme introduces a kink in the pepti-
doglycan backbone at positions1 and2 (Fig. 7, A and B). It
would appear that Cpl-1 recognizes the solution structure of
the peptidoglycan (at peptidoglycan-binding site 1) as it distorts
the polysaccharide backbone (at peptidoglycan-binding site 2)
en route to turnover.
It has been suggested that PG glycosyltransferases are pro-
cessive enzymes, meaning that they catalyzemultiple rounds of
coupling without releasing the elongating product. This model
for processive glycosyl chain synthesis has been documented
FIGURE 7. The bacterial cell wall recognition model. A, stereo view representation showing the superposition of the structures observed by x-ray crystal-
lography (Cpl-1E94Q-(2S5P)2 complex; carbons in gray), by computation (Cpl-1-(2S5P)3 complex; carbons in black), and the peptidoglycan solution structure
determined by NMR (carbons in orange). B, protein is drawn as a Connolly solvent-accessible surface, with the same color coding given in Fig. 3A. The
superimpositionof the x-ray and computational andNMR results and their respective color coding are the sameas inA. C, viewsof amolecule of Cpl-1 depicted
as a Connolly surface in green docked on to the cell wall. The peptidoglycan appears in orange (glycan chains) and blue (peptide stems). The PG strand bound
to Cpl-1 is represented as a transparent surface.
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for the PG glycosyltransferase domain of Aquifex aeolicus
recently (37), whose three-dimensional structure resembles
that of the bacteriophage -lysozyme. Although no experi-
mental information on processivity by Cpl-1 is available, the,
structurally related enzyme Cellosyl from S. coelicolor exhib-
its a processive mechanism.4 The experimental demonstra-
tion of processivity waits for Cpl-1, but the structure
reported herein argues that as the hydrolytic reaction pro-
ceeds at the juncture of the peptidoglycan-binding sites 1
and 2, the enzyme might move along the backbone of the
peptidoglycan in performing the catalytic process repeatedly
(Fig. 7B).
The aforementioned right-handed helical conformation of
the peptidoglycan polysaccharide backbone produced a 3-fold
symmetry in the molecule (29). Each peptidoglycan strand is
cross-linked to a neighboring strand to give a continuous cova-
lent network for the cell wall that covers the entire bacterium.
The 3-fold symmetry presents the opportunity for cross-linking
to amaximum of three neighboring strands but requires amin-
imumof two, which led to the proposed honeycomb pattern for
the cell wall (29). This model accommodates openings of as
small as 70 Å or larger in the cell wall. For example, the absence
of a single peptidoglycan strand in the perfect honeycomb gen-
erates an opening of 120 Å. The model of Cpl-1 binding to the
peptidoglycan based on the x-ray structure of the enzyme and
the solution NMR structure of the peptidoglycan depicted in
Fig. 7B can be directly accommodated with this honeycomb
pattern in openings of 120Å (when one strand of peptidoglycan
is missing) or larger (Fig. 7C).
A Common Peptidoglycan Recognition Pattern?—In the fight
against infections, multicellular animals have adapted their
immune system to recognizemicroorganisms by detecting con-
served structures. This recognition constitutes the first line of
defense by the host. Peptidoglycanmolecules are located on the
surface of all Gram-positive bacteria and therefore constitute
an excellent target for recognition by the innate immune sys-
tem such as CD14 and Toll-like receptors, Nod proteins, and
the PGRPs (38, 39). PGRPs are proteins that are highly con-
served from insects to mammals that can bind and, in some
cases, hydrolyze the PG (39–42). Although the majority of the
PGRPs contain a single PG-binding domain, which is structur-
ally related to the bacteriophage T7 lysozyme, some of them
have tandem domains adopting a similar fold. PGRPs act as
conduits linking PG recognition to the induction of intracellu-
lar signaling or complement cascades. To fulfill this role, PGRPs
present a conserved peptidoglycan-binding site and a variable
locus for interacting with the host effector (39, 41, 42). Interest-
ingly, structural comparison of Cpl-1 with the complex of
human PGRPIC bound to MurNAc-L-Ala-D-isoGln-L-Lys
(43) reveals that the PG-binding site in PGRPs is similar in
shape to the PGBS2 of Cpl-1 (supplemental Fig. 2, A and B).
This is remarkable in light of the fact that the two proteins
are unrelated to each other. A more detailed comparison
shows that the nature of the interactions with the ligand is
basically the same and that the conformation of the stem
peptide within the binding site is practically identical in both
cases. In addition, the PGRPIC-MurNAc-L-Ala-D-isoGln-L-
Lys complex revealed that PGRPs interact with both the pep-
tide stems and the glycan backbone of the muropeptides, as we
also found to be the case in Cpl-1. This bindingmode, involving
differential recognition of variable peptide sequences, has been
postulated (43) as the structural basis for host discrimination
among Gram-positive and Gram-negative bacteria. However,
there is an essential difference between PGRPs and Cpl-1
proteins in that Cpl-1 uses multivalent interactions, both in
the catalytic and the choline-binding modules. Furthermore,
the interactions at the catalytic site are more extensive than
is the case of the PGRPs, constituting two sites, which we
refer to as peptidoglycan-binding sites 1 and 2.
Glycosyl hydrolases are key enzymes in reshaping the bacte-
rial cell wall. We have described in this study the structure of
the native pneumococcal phage Cpl-1 lysin in complex with
three cell wall PG analogues. This structural information pro-
vides for the first time insights into how the cell wall is recog-
nized by this enzyme and defines the incremental steps
involved in the catalytic events that lead to hydrolytic fragmen-
tation of the cell wall. In light of the fact that phage lysins such
as Cpl-1 have been documented to have antibacterial effects in
animal models for infections (the word “enzybiotic” has been
coined) our report defines the mechanism of this antibacterial
effect.
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